• Q4 FY26 performance: Underlying volume growth reached 15.3% alongside mid-teens consolidated revenue growth and an EBITDA margin expansion of approximately 300 bps, supported by double-digit growth in Fevicol as well as strong momentum in Dr. Fixit and Raw.
• West Asia headwinds: Hydrocarbon-linked raw material inflation has surged 40% to 50% due to the regional conflict, prompting the company to protect supply lines and roll out calibrated price hikes in April and May.
• Capex outlook: Capital expenditure for FY27 will remain within the typical 3% to 5% range, highlighted by the early FY27 commissioning of an automated greenfield premium white glue plant for Fevicol in West India.
• Margin corridor guidance: After achieving a 24.6% EBITDA margin in FY26 due to benign input costs, management expects FY27 margins to remain within its standard 20% to 24% corridor through disciplined execution and price adjustments.